Your browser doesn't support javascript.
loading
Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease.
Sinha, Tanya; Zain, Zukhruf; Bokhari, Syed Faqeer Hussain; Waheed, Sarosh; Reza, Taufiqa; Eze-Odurukwe, Anthony; Patel, Mitwa; Almadhoun, Mohammed Khaleel I Kh; Hussain, Azlaan; Reyaz, Ibrahim.
Afiliación
  • Sinha T; Medical Education, Tribhuvan University, Kirtipur, NPL.
  • Zain Z; Family Medicine, Aga Khan University Hospital, Karachi, PAK.
  • Bokhari SFH; Surgery, King Edward Medical University, Lahore, PAK.
  • Waheed S; Medicine, Gujranwala Medical College, Gujranwala, PAK.
  • Reza T; Medicine, Avalon University School of Medicine, Youngstown, USA.
  • Eze-Odurukwe A; Surgery, Salford Royal NHS Foundation Trust, Manchester, GBR.
  • Patel M; Medicine, David Tvildiani Medical University, Tbilisi, GEO.
  • Almadhoun MKIK; Medicine and Surgery, Mutah University, Karak, JOR.
  • Hussain A; Medicine and Surgery, Mayo Hospital, Lahore, PAK.
  • Reyaz I; Internal Medicine, Christian Medical College and Hospital, Ludhiana, IND.
Cureus ; 16(2): e55268, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38558708
ABSTRACT
Inflammatory bowel disease (IBD) presents a complex interplay of chronic inflammation in the gastrointestinal tract and is associated with various extraintestinal manifestations, including cardiovascular complications (CVCs). IBD patients face an elevated risk of CVCs, including coronary artery disease, heart failure, arrhythmias, stroke, peripheral artery disease, venous thromboembolism, and mesenteric ischemia, necessitating comprehensive cardiovascular risk assessment and management. The intricate interplay between chronic inflammation, genetic predisposition, environmental factors, and immune dysregulation likely contributes to the development of CVCs in IBD patients. While the exact mechanisms linking IBD and CVCs remain speculative, potential pathways may involve shared inflammatory pathways, endothelial dysfunction, dysbiosis of the gut microbiome, and traditional cardiovascular risk factors exacerbated by the chronic inflammatory state. Moreover, IBD medications, particularly corticosteroids, may impact cardiovascular health by inducing hypertension, insulin resistance, and dyslipidemia, further amplifying the overall CVC risk. Lifestyle factors such as smoking, obesity, and dietary habits may also exacerbate cardiovascular risks in individuals with IBD. Lifestyle modifications, including smoking cessation, adoption of a heart-healthy diet, regular exercise, and optimization of traditional cardiovascular risk factors, play a fundamental role in mitigating CVC risk. Emerging preventive strategies targeting inflammation modulation and gut microbiome interventions hold promise for future interventions, although further research is warranted to elucidate their efficacy and safety profiles in the context of IBD. Continued interdisciplinary collaboration, advanced research methodologies, and innovative interventions are essential to address the growing burden of CVCs in individuals living with IBD and to improve their long-term cardiovascular outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article